Evidence map›Paper›PMID 36080446›Full record

ReviewMolecules (Basel, Switzerland)2022

The Chemical and Pharmacological Research Progress on a Kind of Chinese Herbal Medicine,

Xiaoyu Li, Xianglei Wang, Menglu Zhao, He Zhang, Chao Liu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Xiaoyu LiNanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, China.
Xianglei WangNanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, China.
Menglu ZhaoPharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-1192, Ishikawa, Japan.
He ZhangDepartment of Pharmacy, The Affiliated Dongnan Hospital of Xiamen University, Zhangzhou 363000, Fujian, China.
Chao LiuDepartment of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, Jiangsu, China.
Nanjing University of Chinese Medicine · CNKanazawa University · JPXiamen University · CN

Funding

National Key Research and Development Plan of China No. 2019YFC1711000National Natural Science Foundation of China No. 81503365National Natural Science Foundation of China No. 81873094
6 · The paper itself

Abstract

Since the outbreak of the COVID-19 pandemic, traditional Chinese medicine has played an important role in the treatment process. Furthermore, the discovery of artemisinin in

Indexed as

COVID-19 Drug TreatmentDrugs, Chinese HerbalFruitHumansMedicine, Chinese TraditionalPandemicsDrugs, Chinese Herbalanti-diabetesanti-tumorchemical constituentsChinese herbal medicineFructus Malvaenortangeretin-8-O-β-d-glucuronopyranosidepharmacological activity

Identifiers

PMID36080446
PMCPMC9458057
OpenAlexW4295007638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.